These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 28336814)

  • 21. Autophagy in skeletal muscle: implications for Pompe disease.
    Shea L; Raben N
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1(Suppl 1):S42-7. PubMed ID: 20040311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.
    Fraites TJ; Schleissing MR; Shanely RA; Walter GA; Cloutier DA; Zolotukhin I; Pauly DF; Raben N; Plotz PH; Powers SK; Kessler PD; Byrne BJ
    Mol Ther; 2002 May; 5(5 Pt 1):571-8. PubMed ID: 11991748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease.
    Farah BL; Madden L; Li S; Nance S; Bird A; Bursac N; Yen PM; Young SP; Koeberl DD
    FASEB J; 2014 May; 28(5):2272-80. PubMed ID: 24448824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What's new and what's next for gene therapy in Pompe disease?
    Roger AL; Sethi R; Huston ML; Scarrow E; Bao-Dai J; Lai E; Biswas DD; El Haddad L; Strickland LM; Kishnani PS; ElMallah MK
    Expert Opin Biol Ther; 2022 Sep; 22(9):1117-1135. PubMed ID: 35428407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease.
    Sun B; Li S; Bird A; Yi H; Kemper A; Thurberg BL; Koeberl DD
    J Gene Med; 2010 Nov; 12(11):881-91. PubMed ID: 20967919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of Pompe disease on smooth muscle: a review.
    McCall AL; Salemi J; Bhanap P; Strickland LM; Elmallah MK
    J Smooth Muscle Res; 2018; 54(0):100-118. PubMed ID: 30787211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Akt inactivation induces endoplasmic reticulum stress-independent autophagy in fibroblasts from patients with Pompe disease.
    Nishiyama Y; Shimada Y; Yokoi T; Kobayashi H; Higuchi T; Eto Y; Ida H; Ohashi T
    Mol Genet Metab; 2012 Nov; 107(3):490-5. PubMed ID: 23041259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adult glycogenosis type II (Pompe's disease): morphological abnormalities in muscle and skin biopsies compared with acid alpha-glucosidase activity.
    Wierzba-Bobrowicz T; Lewandowska E; Lugowska A; Rola R; Stepień T; Ryglewicz D; Pasennik E
    Folia Neuropathol; 2007; 45(4):179-86. PubMed ID: 18176891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice.
    Ziegler RJ; Bercury SD; Fidler J; Zhao MA; Foley J; Taksir TV; Ryan S; Hodges BL; Scheule RK; Shihabuddin LS; Cheng SH
    Hum Gene Ther; 2008 Jun; 19(6):609-21. PubMed ID: 18500944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Murine muscle cell models for Pompe disease and their use in studying therapeutic approaches.
    Takikita S; Myerowitz R; Zaal K; Raben N; Plotz PH
    Mol Genet Metab; 2009 Apr; 96(4):208-17. PubMed ID: 19167256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
    Han SO; Li S; Bird A; Koeberl D
    Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of systemic follistatin as an adjuvant to stimulate muscle repair and improve motor function in Pompe mice.
    Foley JW; Bercury SD; Finn P; Cheng SH; Scheule RK; Ziegler RJ
    Mol Ther; 2010 Sep; 18(9):1584-91. PubMed ID: 20551907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease.
    Todd AG; McElroy JA; Grange RW; Fuller DD; Walter GA; Byrne BJ; Falk DJ
    Ann Neurol; 2015 Aug; 78(2):222-34. PubMed ID: 25925726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy.
    McCall AL; Stankov SG; Cowen G; Cloutier D; Zhang Z; Yang L; Clement N; Falk DJ; Byrne BJ
    Curr Gene Ther; 2019; 19(3):197-207. PubMed ID: 31223086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defects.
    Colella P; Sellier P; Gomez MJ; Biferi MG; Tanniou G; Guerchet N; Cohen-Tannoudji M; Moya-Nilges M; van Wittenberghe L; Daniele N; Gjata B; Krijnse-Locker J; Collaud F; Simon-Sola M; Charles S; Cagin U; Mingozzi F
    EBioMedicine; 2020 Nov; 61():103052. PubMed ID: 33039711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dysregulation of multiple facets of glycogen metabolism in a murine model of Pompe disease.
    Taylor KM; Meyers E; Phipps M; Kishnani PS; Cheng SH; Scheule RK; Moreland RJ
    PLoS One; 2013; 8(2):e56181. PubMed ID: 23457523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α.
    Kishnani P; Tarnopolsky M; Roberts M; Sivakumar K; Dasouki M; Dimachkie MM; Finanger E; Goker-Alpan O; Guter KA; Mozaffar T; Pervaiz MA; Laforet P; Levine T; Adera M; Lazauskas R; Sitaraman S; Khanna R; Benjamin E; Feng J; Flanagan JJ; Barth J; Barlow C; Lockhart DJ; Valenzano KJ; Boudes P; Johnson FK; Byrne B
    Mol Ther; 2017 May; 25(5):1199-1208. PubMed ID: 28341561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene Therapy for Pompe Disease: The Time is now.
    Colella P; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enzyme replacement therapy in the mouse model of Pompe disease.
    Raben N; Danon M; Gilbert AL; Dwivedi S; Collins B; Thurberg BL; Mattaliano RJ; Nagaraju K; Plotz PH
    Mol Genet Metab; 2003; 80(1-2):159-69. PubMed ID: 14567965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycosylation-independent lysosomal targeting of acid α-glucosidase enhances muscle glycogen clearance in pompe mice.
    Maga JA; Zhou J; Kambampati R; Peng S; Wang X; Bohnsack RN; Thomm A; Golata S; Tom P; Dahms NM; Byrne BJ; LeBowitz JH
    J Biol Chem; 2013 Jan; 288(3):1428-38. PubMed ID: 23188827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.